PriceTargets.com logo

Medifast - MED Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $17.00
  • Forecasted Upside: -8.55%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$18.59 As of 12/17/2024 01:00 AM ET
▲ +0.36 (1.97%)

This chart shows the closing price for MED by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medifast Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MED and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MED

Analyst Price Target is $17.00
▼ -8.55% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Medifast in the last 3 months. The average price target is $17.00, with a high forecast of $17.00 and a low forecast of $17.00. The average price target represents a -8.55% upside from the last price of $18.59.

This chart shows the closing price for MED for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in Medifast. This rating has held steady since October 2024, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/5/2024DA DavidsonUpgradeUnderperform ➝ Neutral$16.50 ➝ $17.00
7/22/2024DA DavidsonReiterated RatingUnderperform ➝ Underperform$17.50 ➝ $17.50
6/5/2024DA DavidsonDowngradeNeutral ➝ Underperform$25.00 ➝ $17.50
4/30/2024DA DavidsonLower TargetNeutral ➝ Neutral$40.00 ➝ $25.00
2/21/2024DA DavidsonLower TargetNeutral ➝ Neutral$67.00 ➝ $40.00
10/13/2023StephensInitiated CoverageEqual Weight$82.00
8/8/2023DA DavidsonLower TargetNeutral ➝ Neutral$93.00 ➝ $80.00
7/31/2023DA DavidsonBoost TargetNeutral ➝ Neutral$75.00 ➝ $93.00
6/22/2023DA DavidsonBoost Target$71.00 ➝ $75.00
5/2/2023DA DavidsonLower Target$94.00 ➝ $71.00
2/22/2023DA DavidsonLower TargetNeutral$106.00 ➝ $94.00
11/4/2022DA DavidsonDowngradeBuy ➝ Neutral$278.00 ➝ $106.00
8/4/2022DA DavidsonLower TargetBuy$352.00 ➝ $278.00
8/4/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$345.00 ➝ $150.00
6/2/2022DA DavidsonBoost TargetBuy$341.00 ➝ $352.00
2/24/2022DA DavidsonLower TargetBuy$349.00 ➝ $341.00
11/8/2021DA DavidsonLower TargetBuy$395.00 ➝ $349.00
8/23/2021DA DavidsonReiterated RatingBuyC$395.00
5/5/2021B. RileyBoost TargetBuy$310.00 ➝ $400.00
5/5/2021DA DavidsonBoost TargetBuy$302.00 ➝ $395.00
3/4/2021DA DavidsonBoost TargetBuy$239.00 ➝ $302.00
2/26/2021DA DavidsonBoost TargetBuy$239.00 ➝ $302.00
2/26/2021B. RileyBoost TargetBuy$300.00 ➝ $310.00
2/19/2021B. RileyBoost TargetBuy$250.00 ➝ $300.00
1/25/2021Jefferies Financial GroupUpgradeHold ➝ Buy$205.00 ➝ $265.00
1/12/2021DA DavidsonBoost TargetPositive ➝ Buy$205.00 ➝ $239.00
11/5/2020DA DavidsonUpgradeNeutral ➝ Buy$180.00 ➝ $205.00
11/3/2020B. RileyBoost TargetBuy$230.00 ➝ $250.00
10/9/2020B. RileyBoost Target$220.00 ➝ $230.00
10/1/2020Jefferies Financial GroupUpgradeBuy$210.00
8/10/2020DA DavidsonBoost TargetNeutral$86.00 ➝ $180.00
8/6/2020B. RileyBoost Target$164.00 ➝ $220.00
6/25/2020B. RileyInitiated CoverageBuy$164.00
5/6/2020DA DavidsonBoost TargetNeutral$83.00 ➝ $86.00
2/27/2020DA DavidsonBoost TargetNeutral$74.00 ➝ $83.00
2/27/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$130.00 ➝ $90.00
1/14/2020Jefferies Financial GroupBoost TargetBuy$110.00 ➝ $130.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 13 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
5/22/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 4 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 8 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/19/2024
  • 8 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 2 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 5 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 5 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Medifast logo
Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.
Read More

Today's Range

Now: $18.59
Low: $18.13
High: $19.07

50 Day Range

MA: $18.79
Low: $17.31
High: $21.77

52 Week Range

Now: $18.59
Low: $17.07
High: $70.58

Volume

194,313 shs

Average Volume

371,442 shs

Market Capitalization

$203.34 million

P/E Ratio

28.17

Dividend Yield

N/A

Beta

1.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Medifast?

The following Wall Street research analysts have issued research reports on Medifast in the last twelve months: DA Davidson, and TheStreet.
View the latest analyst ratings for MED.

What is the current price target for Medifast?

0 Wall Street analysts have set twelve-month price targets for Medifast in the last year. Their average twelve-month price target is $17.00, suggesting a possible downside of 8.6%. DA Davidson has the highest price target set, predicting MED will reach $17.00 in the next twelve months. DA Davidson has the lowest price target set, forecasting a price of $17.00 for Medifast in the next year.
View the latest price targets for MED.

What is the current consensus analyst rating for Medifast?

Medifast currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MED, but not buy more shares or sell existing shares.
View the latest ratings for MED.

What other companies compete with Medifast?

Other companies that are similar to Medifast include Herbalife, USANA Health Sciences, Nu Skin Enterprises, Nature's Sunshine Products and Veru. Learn More about companies similar to Medifast.

How do I contact Medifast's investor relations team?

Medifast's physical mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer's listed phone number is (410) 581-8042 and its investor relations email address is [email protected]. The official website for Medifast is www.medifast1.com. Learn More about contacing Medifast investor relations.